"LOTEMAX SM is the culmination of our clinical experience with the loteprednol etabonate compound for more than two decades. We are extremely proud to make this new treatment option available, our ...

LOTEMAX SM Is Formulated with SubMicron Technology for Efficient Penetration To Key Ocular Tissues 1 BRIDGEWATER, N.J., Feb. 25, 2019 /CNW/ -- Bausch + Lomb, a leading global eye health company and ...

Bausch + Lomb has announced it has received FDA approval of the company’s new drug application for LOTEMAX 0.5 percent gel drop formulation, according to a news release. The LOTEMAX (loteprednol ...